Select a community
Parkinson's
Find out more about the PatientsLikeMe
Parkinson's Community
Home > Community Treatment Reports > Celecoxib Treatment Report
What is Celecoxib?

Celecoxib is a non-steroidal antiinflammatory used to relieve the pain, swelling and stiffness of osteoarthritis and adult rheumatoid arthritis; to treat of primary dysmenorrhea; and to reduce intestinal polyps in the inherited disorder adenomatous polyposis.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken
# of patients Efficacy
Major
Moderate
Slight
None
Can’t tell
# of patients evaluated by
Other 4 2
Arthritis 3 0
Joint pain 2 1
General health 2 0
Mobility 2 1
Pain 1 0

See all 13 patients currently taking Celecoxib

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
0 0%
None
5 100%

Dosages

  50 mg daily 100 mg daily 200 mg daily 400 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 8 Number of Patients: 8 3 Number of Patients: 3  

Stop Reasons

Why Patients Stopped Taking Celecoxib (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other
3 60% Other: 60%
Did not seem to work
1 20% Did not seem to work: 20%
Expense
1 20% Expense: 20%
Side effects too severe
1 20% Side effects too severe: 20%

See all 5 patients who’ve stopped taking Celecoxib

Currently Taking Celecoxib

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking Celecoxib

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
4 80%
Usually
0 0%
Sometimes
1 20%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
1 20%
Not at all
4 80%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
2 40%
$25-49
1 20%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on March 20, 2010.